JBC: Scientists fill in a piece of the copper transport puzzle
Researchers have identified the protein that carries copper into mitochondria, where copper is required for the functioning of the cell’s energy conversion machinery. The discovery, published in the Journal of Biological Chemistry, fills in a piece of the puzzle of how copper is distributed and used in the cell.
Mitochondria, the powerhouses of the cell, need copper to produce energy. Copper enters the mitochondria through a previously identified phosphate transporter.Courtesy of Paul Cobine and Xinyu Zhu/Auburn University Humans acquire copper in trace amounts from food. Despite its low levels, copper is essential for the functioning of numerous important enzymes, such as some of those involved in synthesizing collagen and neurotransmitters. Notably, copper is required for building cytochrome c oxidase, known as COX, a large protein complex in mitochondria that forms the last step of the electron transport chain, which harvests energy for the production of ATP, the energy currency of the cell.
Paul Cobine of Auburn University and his collaborator Scot Leary at the University of Saskatchewan have been working for more than 10 years on understanding how copper is used to assemble COX. One basic question was, how does copper get across the membranes in mitochondria?
“To get (copper) to the correct address (in the cell) without interfering with other proteins, or disrupting other targets that have a high chance of binding copper, is a herculean delivery effort,” Cobine said. “This is akin to finding your way to an exit in a crowded bar without touching the other people or getting redirected. Then after finding the exit, you must make sure you go through the right door.”
The researchers used multiple lines of evidence to arrive at an answer: Copper is transported within mitochondria by a protein called SLC25A3. This discovery was surprising because SLC25A3 was already known to transport phosphate, a negatively charged ion, whereas copper ions carry a positive charge. The researchers speculate that the copper ions may need to bind to another partner, forming a negatively charged complex, for SLC25A3 to be able to transport it. The next question they want to address is how the transporter distinguishes between its different types of cargo.
Previously known mutations in the gene encoding SLC25A3 are responsible for poorly understood genetic disorders involving dysfunctional heart and muscle fibers, leading to enlarged hearts and low muscle tone. As these tissues require large amounts of energy, it seems plausible that these patients’ symptoms could be related to insufficient copper transport in mitochondria.
These symptoms “all sound like they could be related to both ATP production and cytochrome c oxidase,” Cobine said.
With the discovery of the copper transport pathway within mitochondria, the health effects of copper can be studied in more detail because researchers will be able to distinguish the effects of copper on COX from the other pathways it’s involved in.
“If we don’t deal with copper properly throughout our life, what are the metabolic diseases that come up?” Cobine asks. “Now we have the ability to look at what happens when you lose mitochondrial copper at different (developmental) stages.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Cholesterol regulatory genes predict liver transplant outcomes
Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.